Day One Biopharmaceuticals
DAWN
DAWN was delisted on the 22nd of April, 2026.
174 hedge funds and large institutions have $605M invested in Day One Biopharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 54 increasing their positions, 61 reducing their positions, and 32 closing their positions.
300% more funds holding in top 10
Funds holding in top 10: 1 → 4 (+3)
48% more call options, than puts
Call options by funds: $641K | Put options by funds: $432K
3% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 32
0% more funds holding
Funds holding: 174 → 174 (0)
2% less capital inflows, than outflows
Capital inflows: $91.9M | Capital outflows: $94M
1.43% less ownership
Funds ownership: 85.16% → 83.73% (-1.4%)
11% less repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 61
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Rubric Capital Management (New York)
New York
|
+$23.2M |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$10.5M |
| 3 |
MAK Capital One
New York
|
+$10M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$9.5M |
| 5 |
Deerfield Management
New York
|
+$6.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Polar Capital Holdings
London,
United Kingdom
|
-$13.7M |
| 2 |
Pictet Asset Management
Carouge,
Switzerland
|
-$9.29M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.57M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$7.16M |
| 5 |
BlackRock
New York
|
-$5.7M |
DAWN Hedge Fund Activity: Q3 2025 in Review
174 of the 7,661 institutional investors tracked by Wall St. Rank reported a position in Day One Biopharmaceuticals (DAWN) for Q3 2025, worth a combined $605M — up 7.8% from $561M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new DAWN positions and 32 closed out — a net gain of 1 holder — while 54 added to existing stakes and 61 trimmed.
The largest buyer was Rubric Capital Management (New York), opening a new position worth an estimated $23.2M. The largest seller was Polar Capital Holdings, exiting entirely with an estimated $13.7M sold.
- 174 institutional investors held Day One Biopharmaceuticals (DAWN) as of Q3 2025, unchanged from Q2 2025.
- Funds reported $605M of Day One Biopharmaceuticals stock for Q3 2025, up 7.8% quarter-over-quarter.
- 33 funds opened new Day One Biopharmaceuticals positions in Q3 2025 and 32 closed out, a net change of +1 holder.
- The largest Day One Biopharmaceuticals buyer in Q3 2025 was Rubric Capital Management (New York), an estimated $23.2M added.
- The largest Day One Biopharmaceuticals seller in Q3 2025 was Polar Capital Holdings, an estimated $13.7M sold.
Based on aggregated 13F filings for Q3 2025.